

Electronic Acknowledgement Receipt

EFS ID:	1251827
Application Number:	10526285
Confirmation Number:	4683
Title of Invention:	Pharmaceutical composition of metaxalone with enhanced oral bioavailability
First Named Inventor:	Nitin Bhalachandra Dharmadhikari
Customer Number:	22908
Filer:	Robert H. Resis/Alma Bahena
Filer Authorized By:	Robert H. Resis
Attorney Docket Number:	006420.00004
Receipt Date:	13-OCT-2006
Filing Date:	02-MAR-2005
Time Stamp:	13:46:55
Application Type:	U.S. National Stage under 35 USC 371
International Application Number:	

Payment information:

Submitted with Payment	yes
Payment was successfully received in RAM	\$300
RAM confirmation Number	1181
Deposit Account	190733
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows: Charge any Additional Fees required under 37 C.F.R. Section 1.16 and 1.17	

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)	Multi Part	Pages				
1		Amendment04.pdf	902105	yes	15				
	Multipart Description								
	Doc Desc		Start	End					
	Amendment After Final		1	1					
	Specification		2	2					
	Claims		3	5					
	Applicant Arguments/Remarks Made in an Amendment		6	15					
Warnings:									
Information:									
2	Extension of Time	Extension04.pdf	89195	no	1				
Warnings:									
Information:									
3	Information Disclosure Statement (IDS) Filed	SupplementalIDS04.pdf	671209	no	4				
Warnings:									
Information:									
A U.S. Patent Number Citation or a U.S. Publication Number Citation is required in the Information Disclosure Statement (IDS) form for autoloading of data into USPTO systems. You may remove the form to add the required data in order to correct the Informational Message if you are citing U.S. References. If you chose not to include U.S. References, the image of the form will be processed and be made available within the Image File Wrapper (IFW) system. However, no data will be extracted from this form. Any additional data such as Foreign Patent Documents or Non Patent Literature will be manually reviewed and keyed into USPTO systems.									
4	NPL Documents	Ref1.pdf	2292510	no	12				
Warnings:									
Information:									
5	NPL Documents	Ref2.pdf	718451	no	4				
Warnings:									
Information:									
6	NPL Documents	Ref3.pdf	1132165	no	6				
Warnings:									

Information:					
7	NPL Documents	Ref4.pdf	446891	no	4
Warnings:					
Information:					
8	Fee Worksheet (PTO-875)	fee-info.pdf	8361	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			6260887		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p>					